Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRecruitment status was updated to not recruiting. The history now shows a new revision: v3.6.0, with the prior revision v3.5.5 removed.SummaryDifference0.4%

- Check8 days agoChange DetectedA new revision entry v3.5.5 was added to the history, and the previous revision v3.5.4 was removed from the history.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA new revision entry v3.5.4 has been added to the study's record history, and the older entry v3.5.3 has been removed. This update reflects an adjustment to the visible version history of the record rather than changes to the study details.SummaryDifference0.1%

- Check44 days agoChange DetectedA new revision entry v3.5.3 was added to the record history. The previous revision v3.5.2 was removed from the list.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page updates its displayed software revision from v3.5.0 to v3.5.2. No trial-specific content changes are shown.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded a new version entry: Revision: v3.5.0, and removed the entry: Revision: v3.4.3, in the study record history.SummaryDifference0.1%

Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.